Termeer-backed ProQR lays out terms for $75M IPO

The Dutch biotech ProQR, which has rounded up cash from a group of backers that includes former Genzyme CEO Henri Termeer, has laid out its proposed terms for a $75 million IPO. The biotech, which is focused on the role of messenger RNA in cystic fibrosis, plans to sell 6.3 million shares at $11 to $13 a share. The company, which is tackling the same patient population as Boston-based Vertex ($VRTX), has plans to file an IND on its lead drug later this year. After that Termeer and his group of well-connected biotech execs who are advising the company--which includes Dinko Valerio, the former CEO of J&J's ($JNJ) Crucell--expect to take the program all the way through to commercialization. Story

Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.